NANO Nanobiotix SA

Voting Rights and Shares Capital of the Company

Voting Rights and Shares Capital of the Company

PARIS, April 11, 2023 (GLOBE NEWSWIRE) --

In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)

Paris, France, April 11, 2023

Market: Euronext Paris / Nasdaq

Euronext Compartment: B

ISIN code: FR0011341205

Nasdaq: NBTX

Bloomberg: NANO:FP

Reuters: NANO.PA

Website:

Date



Number of Shares Outstanding







Total number of voting rights
Total voting rights, theoretical1



Total voting rights,

exercisable2
March 31, 2023



34,875,87236,634,84936,612,731

According to the article L.233-8 II of the French Commercial Code, Nanobiotix will make a new monthly publication of the total number of voting rights and shares comprising Nanobiotix’s capital if those figures differ from the information previously disclosed.

About NANOBIOTIX

Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The company is leveraging its proprietary nanoparticle platform, including its lead product candidate, radiotherapy activated NBTXR3, to develop a pipeline of therapeutic options designed to enhance local and systemic control of solid tumors with an initial focus on the treatment of head and neck cancers. 

For more information about Nanobiotix, visit us at or follow us on and . 

Contacts

Nanobiotix     




Nanobiotix Communications

Brandon Owens

VP, Communications

+1 (617) 852-4835









Nanobiotix Investor Relations

Craig West

SVP, Investor Relations

+1 (617) 583-0211 





    
Media Relations  
France – Ulysse Communication

Pierre-Louis Germain

+ 33 (0) 6 64 79 97 51





LifeSci Advisors 

Ligia Vela-Reid 

+44 (0) 7413825310 

 



  

 

1 The total number of theoretical (or “gross”) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.

2 The total number of exercisable at a Shareholders’ Meeting (or “net”) voting rights is calculated without taking into account shares for which voting rights have been suspended as shares held in treasury by the Company. It is released in order to ensure that the public is properly informed, in accordance with the AMF recommendation of July 17, 2007.

 

Attachment



EN
11/04/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Nanobiotix SA

 PRESS RELEASE

Information mensuelle relative au nombre total de droits de vote et d’...

Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social Conformément aux articles L.233-8 II du Code de commerce et 223-16 du Règlement Général de l’Autorité des Marchés Financiers PARIS, 15 oct. 2025 (GLOBE NEWSWIRE) -- Place de cotation : Euronext Paris / NasdaqEuronext Compartiment : B Code ISIN : FR0011341205Nasdaq : NBTXBloomberg : NANO:FPReuters : NANO.PASite web : DateNombre total d’actionscomposant le capitalsocialNombre total de droits de voteTotal théorique1Total exerçable230 septembre 202548 237 47150 318 25750 296 139 À prop...

 PRESS RELEASE

Voting Rights and Shares Capital of the Company

Voting Rights and Shares Capital of the Company In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Market: Euronext Paris / NasdaqEuronext Compartment: B ISIN code: FR0011341205Nasdaq: NBTXBloomberg: NANO:FPReuters: NANO.PAWebsite: DateNumber of SharesOutstandingTotal number of voting rightsTotal voting rights,theoretical1Total voting rights,exercisable2September 30, 202548,237,47150,318,25750,296,139   About NAN...

 PRESS RELEASE

NANOBIOTIX Announces First Data From Phase 1 Study Evaluating JNJ-1900...

NANOBIOTIX Announces First Data From Phase 1 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Esophageal Cancer Treatment was well-tolerated and injection feasibility was confirmed in 13 patients with locally advanced adenocarcinoma of the esophagus85% (11/13) disease control rate (DCR)69% (9/13) objective response rate (ORR); 6 complete responses and 3 partial responsesRecruitment of 17 additional patients is ongoing as planned Data presented at the 2025 Annual Meeting of the American Society for Radiation Oncology (ASTRO) on October 1st PARIS and CAMBRIDGE, Mass., Oct. 01, 2025 (G...

 PRESS RELEASE

NANOBIOTIX annonce les premières données de Phase 1 évaluant JNJ-1900 ...

NANOBIOTIX annonce les premières données de Phase 1 évaluant JNJ-1900 (NBTXR3) chez des patients atteints de cancer de l’œsophage Le traitement a été bien toléré et la faisabilité de l’injection a été confirmée chez les 13 patients atteints d’adénocarcinome de l’œsophage localement avancé.Le taux de contrôle de la maladie (DCR, disease control rate) était de 85 % (11/13).Le taux de réponse objective (ORR, overall response rate) était de 69 % (9/13) avec 6 réponses complètes et 3 réponses partielles.Le recrutement de 17 patients supplémentaire est en cours. Données présentées le 1 octobre a...

 PRESS RELEASE

NANOBIOTIX Provides Business Update and Reports Half Year 2025 Financi...

NANOBIOTIX Provides Business Update and Reports Half Year 2025 Financial Results PARIS and CAMBRIDGE, Mass., Sept. 30, 2025 (GLOBE NEWSWIRE) -- (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, provided an update on operational progress and announced its half year financial results for the six-month period ended June 30, 2025. Operational Highlights of the 2025 Half Year Period and To Date Expanding clinical development ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch